October 5, 2009 β A new analysis reaffirms that Lexiscan (regadenoson) Injection, the first selective A2A ...
Pharmaceuticals
This channel includes news and new technology innovations for cardiovascular pharmaceutics. This includes antiplatelet agents, anticoagulation drugs, INR testing, NOAC, OAC, IV administered drugs such as Heprin, and dual antiplatelet therapy.
September 28, 2009 β New data from the phase III PLATO study showed that ticagrelor (BRILINTA) provided 16 ...
September 29, 2009
September 28, 2009 β Sanofi-aventis announced last week the Committee for Medicinal Products for Human Use (CHMP) ...
September 29, 2009
September 18, 2009 β Patientsβ response to anti-platelet therapy after percutaneous coronary intervention (PCI) ...
September 18, 2009
September 18, 2009 β The FDA has approved Valturna (aliskiren and valsartan) tablets, the first and only medicine ...
September 18, 2009September 17, 2009 β The 13th Annual Scientific Meeting of the Heart Failure Society of America (HFSA) on ...
September 17, 2009
Feature | Dave Fornell
In August Daiichi Sankyo and Eli Lilly and Company launched U.S. sales of Effient (prasugrel), a new antiplatelet ...
September 17, 2009September 14, 2009 β The 13th Annual Scientific Meeting of the Heart Failure Society of America (HFSA) today ...
September 14, 2009
Feature | Dave Fornell
Gregg W. Stone, M.D., offered a preview Sept. 10 of some of the key, late-breaking clinical trials and trends in ...
September 10, 2009
September 10, 2009 β Regado Biosciences said this week it enrolled the first patient in a phase 2b, randomized ...
September 10, 2009
September 8, 2009 β Actelion Pharmaceuticals U.S. Inc. recently announced the first commercial sales of a new 20 ...
September 08, 2009
September 3, 2009 β Important new findings in patients with angina participating in the BEAUTIFUL study show that ...
September 03, 2009
September 3, 2009 β The OASIS study group presented initial results of the CURRENT-OASIS 7 clinical trial Sunday ...
September 03, 2009September 2, 2009 β A new analysis from the JUPITER study showed CRESTOR (rosuvastatin calcium) 20 mg reduced the ...
September 02, 2009
September 1, 2009 β Cordis Corp. said first patient has been enrolled in the CYPRESS study, which will assess ...
September 01, 2009Β© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now